REG - hVIVO PLC - Capital Markets Day

hVIVOAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260520:nRST9866Ea&default-theme=true

RNS Number : 9866E  hVIVO PLC  20 May 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

hVIVO to showcase integrated, full service early clinical development platform
at Capital Markets Day

 

Speakers from Boehringer Ingelheim, RA Capital, ILiAD Biotechnologies and
Decoy Therapeutics to discuss hVIVO's clinical development offering

 

London, UK - 20 May 2026, hVIVO plc (AIM: HVO), a purpose-built,
full-service international clinical development partner and the world leader
in human challenge trials, announces that it will hold a Capital Markets Day
for analysts, institutional investors and media in Canary Wharf on Thursday 11
June 2026 from 09:00 - 13:00 (BST).

 

The event will provide investors with a deeper understanding of hVIVO's
strategic evolution from a specialist human challenge trial provider into a
differentiated, integrated early clinical development partner, supporting
biotechnology and pharmaceutical companies from preclinical strategy through
first-in-human studies, patient trials and specialist laboratory services.

 

Through presentations from clients, investors, industry experts and hVIVO
leadership, the event will explore how the Company's end-to-end platform is
helping sponsors generate high-quality data earlier, accelerate development
timelines and reduce execution risk across the clinical development pathway.

 

The programme will feature real-world case studies, including on hVIVO's role
in supporting Cidara Therapeutics' drug development strategy leading to a $9
billion exit, and a presentation from ILiAD Biotechnologies on the world's
first Phase III pivotal human challenge trial.

 

Discussions will also explore emerging investment trends in infectious
disease, the strategic value of human challenge trials, the increasing
importance of specialist partners in early drug development across Big Pharma
and biotech, and how hVIVO's integrated platform supports faster, more
informed development decisions.

 

External speakers will include:

 

·    Mario Barro, PhD, Head of Infectious Diseases, RA Capital

·    Stephanie Noviello, Chief Medical Officer, ILiAD Biotechnologies

·    Corrina Pavetto, ClinReg Consulting, LLC (formerly SVP Clinical
Development, Cidara Therapeutics)

·    Konstantinos Sinogiannis, Global Category Manager, Boehringer
Ingelheim

·    Rick Pierce, Chief Executive Officer, Decoy Therapeutics

·    Professor Richard Russell, Head of Immunobiology, Professor of
Respiratory Medicine, King's College London

·    Dr Diane Gbesemete, Clinical Research Fellow, University Hospital
Southampton

 

The event will conclude with the opportunity for attendees to tour hVIVO's
Canary Wharf quarantine facility and laboratories.

 

Analysts, institutional investors and media are welcome to attend the event
in-person. Due to capacity constraints, attendance will be limited, however, a
recording of the presentation will be made available on the Company's website
shortly after the event.

 

To register your interest for the Capital Markets Day, please email
hVIVO@icrhealthcare.com.

 

For further information please contact:

 

 hVIVO plc                                                                           +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                                                      +44 (0)20 7220 0500
 Geoff Nash, Callum Davidson

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                                                            +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                                                     +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 ICR Healthcare (Financial PR & IR)                                                  hVIVO@icrhealthcare.com

 Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson

 

Notes to Editors

 

hVIVO plc (https://hvivo.com/) (AIM: HVO) is a purpose-built, full-service
international clinical development partner and the global leader in human
challenge trials, serving seven of the world's ten largest biopharma
companies.

 

The Company has an end-to-end platform designed to bring important medicines
to patients faster: spanning preclinical strategy, first‑in‑human studies,
Phase II patient trials and specialist laboratory services, delivered through
a large participant database, wholly owned sites and laboratories across the
UK and Germany.

 

With a combined Group heritage of more than 100 years, hVIVO delivers an
accelerated pathway to clinical proof-of-concept through four integrated
service lines: Consulting, Clinical Trials, Human Challenge Trials, and
Laboratories.

 

·    Consulting
(https://www.hvivo.com/solutions/drug-development-consulting) provides
expert-led preclinical and clinical strategy, encompassing non-clinical,
clinical, CMC, pharmacokinetics, data management, biostatistics, and
regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials (https://www.hvivo.com/solutions/clinical/) offers
Phase I/II CRO services, Phase II/III site services across the UK and Germany,
and specialist recruitment through FluCamp (http://www.flucamp.com/) ,
Europe's largest recruitment database.

·    Human Challenge Trials
(https://www.hvivo.com/solutions/human-challenge) leverages hVIVO's
state-of-the-art quarantine facility in London - the largest of its kind
worldwide - to deliver fast, controlled, high-quality efficacy data through
guaranteed viral exposure.

·    Laboratories (https://www.hvivo.com/solutions/laboratory) provides
cutting-edge virology and immunology laboratory services, including biobanking
and sample storage, supporting both challenge trials and standalone client
studies.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUMCAUPQGRB



            Copyright 2019 Regulatory News Service, all rights reserved